Atom Investors LP Decreases Stock Holdings in Intra-Cellular Therapies Inc (NASDAQ:ITCI)

Share on StockTwits

Atom Investors LP decreased its position in Intra-Cellular Therapies Inc (NASDAQ:ITCI) by 22.9% during the second quarter, Holdings Channel.com reports. The fund owned 116,579 shares of the biopharmaceutical company’s stock after selling 34,660 shares during the quarter. Atom Investors LP’s holdings in Intra-Cellular Therapies were worth $2,993,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC increased its position in shares of Intra-Cellular Therapies by 4.8% in the second quarter. Nisa Investment Advisors LLC now owns 10,322 shares of the biopharmaceutical company’s stock valued at $265,000 after acquiring an additional 472 shares during the period. Ameritas Investment Partners Inc. boosted its stake in shares of Intra-Cellular Therapies by 22.7% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,589 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 850 shares in the last quarter. US Bancorp DE boosted its stake in shares of Intra-Cellular Therapies by 210.4% during the 1st quarter. US Bancorp DE now owns 1,639 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 1,111 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Intra-Cellular Therapies by 33.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,310 shares of the biopharmaceutical company’s stock valued at $162,000 after purchasing an additional 1,597 shares in the last quarter. Finally, Advisor Group Holdings Inc. bought a new stake in shares of Intra-Cellular Therapies during the 1st quarter valued at about $33,000. Hedge funds and other institutional investors own 71.91% of the company’s stock.

A number of equities research analysts have recently weighed in on ITCI shares. Zacks Investment Research raised shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research note on Friday, August 14th. Canaccord Genuity reaffirmed a “buy” rating and set a $70.00 target price on shares of Intra-Cellular Therapies in a research note on Tuesday, August 11th. ValuEngine raised shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research note on Tuesday, September 1st. Finally, BidaskClub lowered shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $43.17.

NASDAQ:ITCI traded down $0.17 during mid-day trading on Friday, hitting $18.05. 734,249 shares of the company’s stock were exchanged, compared to its average volume of 608,386. Intra-Cellular Therapies Inc has a one year low of $6.75 and a one year high of $43.56. The company has a debt-to-equity ratio of 0.06, a current ratio of 10.40 and a quick ratio of 10.34. The business has a fifty day moving average price of $20.07 and a 200 day moving average price of $20.17. The company has a market cap of $1.21 billion, a PE ratio of -5.90 and a beta of 1.68.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.02). The company had revenue of $1.91 million for the quarter, compared to analyst estimates of $3.05 million. On average, equities analysts forecast that Intra-Cellular Therapies Inc will post -3.72 EPS for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.

Further Reading: What is the strike price in options trading?

Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies Inc (NASDAQ:ITCI).

Institutional Ownership by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply